China Moves 30 Drugs OTC, Encourages Nonprescription Switches
This article was originally published in The Tan Sheet
Executive SummaryChina's State Food and Drug Administration assigned 30 drugs OTC status in a notice issued Jan. 11, reflecting the agency's interest in expanding availability of nonprescription drugs to help reduce health care costs
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.